Glutamic Acid

Glutamic Acid

SCHEMBL2153076

NCCC[C@H](N)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.75
CYP1A2 P05177 2/20 0.75
GRM8 O00222 2/20 0.75
GRM6 O15303 2/20 0.75
GRM7 Q14831 2/20 0.75
GRM4 Q14833 2/20 0.75
GRIN2D O15399 1/20 0.75
GRIN3B O60391 1/20 0.75
GRIK1 P39086 1/20 0.75
GRM5 P41594 1/20 0.75
GRIA1 P42261 1/20 0.75
GRIA2 P42262 1/20 0.75
GRIA3 P42263 1/20 0.75
SLC1A3 P43003 1/20 0.75
SLC1A2 P43004 1/20 0.75
SLC1A1 P43005 1/20 0.75
GRIA4 P48058 1/20 0.75
GRIN1 Q05586 1/20 0.75
GRIN2A Q12879 1/20 0.75
GRIK2 Q13002 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Glutamate SCHEMBL4414452 1.00 GSR (0.75) GSRCYP1A2GRM8GRM6GRM7
D-Glutamate SCHEMBL6850403 1.00 GSR (0.75) GSRCYP1A2GRM8GRM6GRM7
Glutamic Acid SCHEMBL6850406 1.00 GSR (0.75) GSRCYP1A2GRM8GRM6GRM7
D-Glutamate SCHEMBL11310231 1.00 GSR (0.75) GSRCYP1A2GRM8GRM6GRM7
D-Glutamate SCHEMBL8506699 0.96 GSR (0.69) GSRCYP1A2GRM8GRM6GRM7
Glutamic Acid SCHEMBL8506700 0.96 GSR (0.69) GSRCYP1A2GRM8GRM6GRM7
Lysine SCHEMBL205003 0.94 GSR (0.80) GSRCYP1A2GRM8GRM6GRM7
D-Glutamate SCHEMBL21796040 0.94 GSR (0.80) GSRCYP1A2GRM8GRM6GRM7
Lysine SCHEMBL890044 0.94 GSR (0.80) GSRCYP1A2GRM8GRM6GRM7
Lysine SCHEMBL1079952 0.94 GSR (0.80) GSRCYP1A2GRM8GRM6GRM7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1044672-B1 Water-in-oil emulsified cosmetic SHISEIDO CO LTD (JP) 2007-03-07 EP claimed
CN-115976028-B Glycogen disease type Ia therapeutic agent 第一三共株式会社 2025-03-25 CN disclosed
EP-3431605-B1 PUTRESCINE-PRODUCING MICROORGANISM AND METHOD FOR PRODUCING PUTRESCINE USING SAME CJ CHEILJEDANG CORP (KR) 2024-11-06 EP disclosed
CN-118272259-A Strain for fermenting bean dregs into fermentation liquor and application thereof 江西师范大学 2024-07-02 CN disclosed
EP-2492301-B1 NOVEL CO-MODIFIED ORGANOPOLYSILOXANE DOW TORAY CO LTD (JP) 2023-03-29 EP disclosed
US-20220168383-A1 NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) 2022-06-02 US disclosed
EP-3921331-A1 NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN Socpra Sciences Santé Et Humaines S.E.C. (CA) 2021-12-15 EP disclosed
US-11124812-B2 Putrescine-producing microorganism and method for producing putrescine using the same CJ CHEILJEDANG CORPORATION (KR) 2021-09-21 US disclosed
WO-2020160685-A1 NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN SOCPRA Sciences Sante et Humaines S.E.C. (CA) 2020-08-13 WO disclosed
CN-106459888-B Microorganism for producing putrescine and method for producing putrescine using the same CJ第一制糖株式会社 2019-12-24 CN disclosed
US-6210690-B1 SPECIFIC POLYETHER MODIFIED SILICONE, WATER OR WATER AND ETHYL ALCOHOL AS WELL AS A WATER SOLUBLE POLYMER WITH A MOLECULAR WEIGHT OF 2,000-300,000, AN INORGANIC SALT OR AMINO ACID SALT SHISEIDO COMPANY, LTD. (JP) 2001-04-03 US disclosed
EP-1077692-A1 AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME Warner-Lambert Company LLC (US) 2001-02-28 EP disclosed
EP-1044672-A1 Water-in-oil emulsified cosmetic SHISEIDO COMPANY LIMITED (JP) 2000-10-18 EP disclosed
WO-1999059573-A1 STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME WARNER-LAMBERT COMPANY (US) 1999-11-25 WO disclosed
CN-1219119-A Emulsion composition SHISEIDO CO LTD (JP) 1999-06-09 CN disclosed
EP-0914814-A1 EMULSION COMPOSITION SHISEIDO COMPANY LIMITED (JP) 1999-05-12 EP disclosed
EP-0081236-B1 A COMPOUND SEASONING COMPOSITION, A PROCESS FOR ITS PRODUCTION AND ITS USE AS A FOOD COMPONENT AJINOMOTO CO., INC. (JP) 1986-04-23 EP disclosed
US-4563359-A MIXTURE OF GLUTAMIC ACID WITH SODIUM AND POTASSIUM SALTS AJINOMOTO COMPANY, LIMITED (JP) 1986-01-07 US disclosed
EP-0081236-A1 A compound seasoning composition, a process for its production and its use as a food component AJINOMOTO CO., INC. (JP) 1983-06-15 EP disclosed
US-4273684-A Transparent detergent bar AJINOMOTO CO., INC. (JP) 1981-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220168383-A1 NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN VIP, NTSR2, VIPR2 GSR 670/4885CYP1A2 1382/4885GRM8 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.